Dietary ribonucleotides increase antigen-specific type 1 T-helper cells in the regional draining lymph nodes in young BALB/cJ mice☆
Part of this study was presented in the Annual Meeting of Experimental Biology, 2001, held in Orlando, FL, March 31 to April 4, 2001.
Abstract
Objectives
We assessed the mechanisms of ribonucleotide action on type 1 T-helper cell (Th1) responses against ovalbumin (OVA) in Th2-biased BALB/cJ mice.
Methods
Mice were fed a ribonucleotide-free or ribonucleotide-supplemented diet and given OVA subcutaneously with incomplete Freund’s adjuvant at 3 and 6 wk. Costimulatory molecule expression (CD86 and CD154), the state of naive versus effecter/memory Th cells, and the frequency of OVA-specific resting versus activated Th1/Th2 cells were accessed in cells from the regional draining lymph nodes. OVA challenge increased CD86, but not CD154, expression. Effector/memory stage Th/cytotoxic T cells increased after the first and second OVA challenges.
Results
Dietary ribonucleotides did not affect the expression of any of these cell surface molecules. Antigen-specific Th1 and Th2 cells increased 10 d after the first OVA dose and 5 d after the second OVA dose. Further, dietary ribonucleotides increased OVA-specific resting and activated Th1 cells 10 d after the first OVA dose and decreased OVA-specific resting Th2 cells 5 d after the second OVA dose.
Conclusions
Dietary ribonucleotides may attenuate skewed Th2 responses by augmenting clonal expansion of OVA-specific Th1 cells, suppressing expansion of OVA-specific Th2 cells in Th2-biased BLAB/cJ mice, and not affecting antigen non-specific cell surface markers.
aDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA
bRoss Products Division, Abbott Laboratories, Columbus, Ohio, USA
Correspondence to: Harumi Jyonouchi, MD, Division of Allergy/Immunology/ID/Pulmonology, Department of Pediatrics, UMDNJ (University of Medicine and Dentistry of New Jersey) 185 South Orange Ave., Newark, NJ 07103-2714, USA.
☆ This study was supported in part by a grant from the Ross Product Division, Abbott Laboratories, Columbus, Ohio, USA.
ABSTRACT